Poseida Therapeutics, Inc.

DB:2RZ Stock Report

Market Cap: €222.9m

Poseida Therapeutics Balance Sheet Health

Financial Health criteria checks 5/6

Poseida Therapeutics has a total shareholder equity of $60.8M and total debt of $58.8M, which brings its debt-to-equity ratio to 96.7%. Its total assets and total liabilities are $298.7M and $237.9M respectively.

Key information

96.7%

Debt to equity ratio

US$58.80m

Debt

Interest coverage ration/a
CashUS$237.81m
EquityUS$60.82m
Total liabilitiesUS$237.87m
Total assetsUS$298.69m

Recent financial health updates

No updates

Recent updates

Financial Position Analysis

Short Term Liabilities: 2RZ's short term assets ($254.3M) exceed its short term liabilities ($102.4M).

Long Term Liabilities: 2RZ's short term assets ($254.3M) exceed its long term liabilities ($135.4M).


Debt to Equity History and Analysis

Debt Level: 2RZ has more cash than its total debt.

Reducing Debt: 2RZ's debt to equity ratio has increased from 71.7% to 96.7% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable 2RZ has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: 2RZ is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 7.4% per year.


Discover healthy companies